Cargando…
Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750165/ https://www.ncbi.nlm.nih.gov/pubmed/34942993 http://dx.doi.org/10.3390/antiox10121891 |
_version_ | 1784631399187218432 |
---|---|
author | Watanabe, Jun Kotani, Kazuhiko Gugliucci, Alejandro |
author_facet | Watanabe, Jun Kotani, Kazuhiko Gugliucci, Alejandro |
author_sort | Watanabe, Jun |
collection | PubMed |
description | Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on this issue, we performed a meta-analysis of data on PON1 activity in COPD. Electronic databases (MEDLINE, Embase and CENTRAL) were searched for available studies on PON1 activity in patients with stable COPD published before October 2021. A meta-analysis was performed using random-effects models. Twelve studies (12 studies on paraoxonase and three on arylesterase) were identified. Patients with COPD had lower levels of paraoxonase activity (standard mean difference [SMD] −0.77, 95% confidence interval [CI] −1.35 to −0.18) and arylesterase activity (SMD −1.15, 95% CI −1.95 to −0.36) in comparison to healthy controls. In subgroup analyses, paraoxonase activity was lower in patients of studies as consisted of mainly non-severe COPD (SMD −1.42, 95% CI −2.04 to −0.79) and, by contrast, slightly higher in patients of studies including severe COPD (SMD 0.33, 95% CI 0.02 to 0.64) in comparison to healthy controls. Arylesterase activity showed a similar trend. Overall, PON1 activity was lower in patients with COPD, suggesting that PON1-related antioxidant defense is impaired in COPD. Future studies are warranted. |
format | Online Article Text |
id | pubmed-8750165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87501652022-01-12 Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis Watanabe, Jun Kotani, Kazuhiko Gugliucci, Alejandro Antioxidants (Basel) Systematic Review Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on this issue, we performed a meta-analysis of data on PON1 activity in COPD. Electronic databases (MEDLINE, Embase and CENTRAL) were searched for available studies on PON1 activity in patients with stable COPD published before October 2021. A meta-analysis was performed using random-effects models. Twelve studies (12 studies on paraoxonase and three on arylesterase) were identified. Patients with COPD had lower levels of paraoxonase activity (standard mean difference [SMD] −0.77, 95% confidence interval [CI] −1.35 to −0.18) and arylesterase activity (SMD −1.15, 95% CI −1.95 to −0.36) in comparison to healthy controls. In subgroup analyses, paraoxonase activity was lower in patients of studies as consisted of mainly non-severe COPD (SMD −1.42, 95% CI −2.04 to −0.79) and, by contrast, slightly higher in patients of studies including severe COPD (SMD 0.33, 95% CI 0.02 to 0.64) in comparison to healthy controls. Arylesterase activity showed a similar trend. Overall, PON1 activity was lower in patients with COPD, suggesting that PON1-related antioxidant defense is impaired in COPD. Future studies are warranted. MDPI 2021-11-26 /pmc/articles/PMC8750165/ /pubmed/34942993 http://dx.doi.org/10.3390/antiox10121891 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Watanabe, Jun Kotani, Kazuhiko Gugliucci, Alejandro Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
title | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
title_full | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
title_fullStr | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
title_full_unstemmed | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
title_short | Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis |
title_sort | paraoxonase 1 and chronic obstructive pulmonary disease: a meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750165/ https://www.ncbi.nlm.nih.gov/pubmed/34942993 http://dx.doi.org/10.3390/antiox10121891 |
work_keys_str_mv | AT watanabejun paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis AT kotanikazuhiko paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis AT gugliuccialejandro paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis |